Bowave Pharmaceuticals Announces Hypertension siRNA Drug BW-00163 Enters Phase II Clinical Trial and Receives Milestone Payment

On June 5, Argo Biopharma Co., Ltd. (hereinafter referred to as "Argo) announced that itsHypertension Treatment Drug BW-00163AlreadyEnterEntered Phase II clinical trials. This drug is a key component of the company's exclusive licensing agreement with Novartis. As this asset moves intoPhase IIIn clinical development, Argo has received a milestone payment, which will provide important financial support for the company's ongoing innovation.

Dr. Dongxu Shu, Co-founder, Chairman and CEO of Argo Biopharma, stated: "We are very pleased that Novartis has advanced BW-00163 toHypertension TreatmentPhase II Clinical StageNovartis is a global leader in the field of innovative treatments for cardiovascular diseases and also our outstanding partner. We look forward to continuing our cooperation with the Novartis team to accelerate the advancement of this potential new therapy, benefiting patients worldwide.

Argo Biopharma owns a next-generation siRNA platform called RADS, and BW-00163 is the fourth drug developed on this platform to enter mid-stage clinical trials.Record (ClinicalTrials.govTrial Number: NCT06857955）。

Public information shows that Argo Biopharma is a clinical-stage biotechnology company dedicated to developing a new generation of RNAi therapies, aiming to provide better treatment options for patients worldwide. The company has established a rich R&D pipeline, covering multiple therapeutic areas such as cardiovascular and cerebrovascular diseases, viral infections, metabolic diseases, and rare diseases. Currently, six RNAi drug candidates are in clinical development. In January 2024, Argo Biopharma reached two exclusive licensing cooperation agreements with Novartis, receiving an upfront payment of $185 million, with the potential total transaction value exceeding $4 billion.

References:

[1] Argo Biopharma Press Release